Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial.
Name:
Which patients with ES-SCLC are ...
Size:
605.6Kb
Format:
PDF
Description:
Open access full text article
Authors
Slotman, BFaivre-Finn, Corinne
van Tinteren, H
Keijser, A
Praag, J
Knegjens, J
Hatton, M
van Dam, I
van der Leest, A
Reymen, B
Stigt, J
Haslett, Kate
Tripathi, D
Smit, E
Senan, S
Affiliation
VU University Medical Center, Amsterdam, NetherlandsIssue Date
2017-06
Metadata
Show full item recordAbstract
In ES-SCLC patients with residual intrathoracic disease after first-line chemotherapy, the addition of thoracic radiotherapy reduces the risk of intrathoracic recurrence, and improves 2-year survival. To identify patient subgroups for future trials investigating higher dose (extra)thoracic radiotherapy, we investigated the prognostic importance of number and sites of metastases in patients included in the CREST trial.Citation
Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. 2017, 108:150-153 Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2017.03.007PubMed ID
28625628Type
ArticleLanguage
enISSN
1872-8332ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2017.03.007